Cohance Lifesciences Approves ESOP Grants and Share Allotment

Cohance Lifesciences Ltd announced the approval of its Nomination and Remuneration Committee for significant employee stock option (ESOP) activities. The committee approved the in-principle approvals from BSE and NSE for the ESOP 2026 plan. It also sanctioned the grant of up to 1,97,48,317 stock options under ESOP 2026 and 1,74,843 stock options under the ESOP 2023. Additionally, 30,190 equity shares were allotted to employees who exercised options under ESOP 2023. The company also noted the cancellation of 1,87,703 grants previously issued under ESOP 2023.